title: The acute management of venous thromboembolism in pregnancy.
abstract: Pulmonary thromboembolism is the leading cause of maternal death in the UK. Optimal management of deep venous thrombosis and pulmonary thromboembolism requires an appreciation of risk factors, particularly thrombophilia, and signs or symptoms suggestive of venous thromboembolism, along with objective diagnosis and treatment with anticoagulants. Low molecular weight heparins are now replacing unfractionated heparin for the treatment of deep venous thrombosis and pulmonary thromboembolism in pregnancy because of the lower risk of side effects, ease of administration and reduced need for monitoring.
authors.affiliation: Department of Obstetrics and Gynaecology, Royal Infirmary, University of Glasgow, 10 Alexandra Parade, Glasgow G31 2ER, UK. i.a.greer@clinmed.gla.ac.uk
authors.forename: I A
authors.initials: IA
authors.lastname: Greer
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000627:therapeutic use; D002585:Cesarean Section; D005260:Female; D006493:Heparin / Q000008:administration & dosage* / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage; D006801:Humans; D007743:Labor, Obstetric / Q000187:drug effects*; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy* / Q000503:physiopathology; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000209:etiology; D012307:Risk Factors; D020246:Venous Thrombosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin